deCODE and Affymetrix to develop DNA tests:
This article was originally published in Clinica
Icelandic firm deCODE Genetics (Reykjavik) and Affymetrix are to collaborate on the development of DNA-based tests for predicting patients' response to drug treatments for common diseases. Using deCODE's population-based approach to pharmocogenomics and Affymetrix' GeneChip technology, the firms hope to develop tests that will allow for more personalised treatments for common diseases, such as high-cholesterol, depression, asthma, breast cancer, hypertension, schizophrenia and migraine. Affymetrix and deCODE, through its subsidiary Encode, will share the revenues from sales of tests developed under the collaboration.